As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

The Stargate Initiative, spearheaded by several tech giants, has raised alarm in the most paranoid parts of the MAGA movement ...

New research reveals that sunburn may be caused by RNA damage, not DNA, challenging long-held beliefs about UV exposure ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...

The Kowalinski group at EMBL Grenoble discovered notable differences between the nuclear cap-binding complex in trypanosomes and humans, a critical component in cellular RNA metabolism. Trypanosomes ...

Vaxxas Pty. Ltd. and the Coalition for Epidemic Preparedness Innovations are progressing heat-stable, dried-formulation mRNA ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.